Purpose: To evaluate salvage pelvic nodal radiation as an alternative to androgen deprivation therapy (ADT) in patients with biochemical failure and lymph node recurrence following salvage prostate fossa radiation.
Methods: Six patients with biochemical failure and lymph node recurrence following prostate fossa radiation were treated with salvage pelvic nodal radiation therapy. A gross target volume was contoured using Choline PET/CT, CT, or MRI imaging. The clinical target volume included pelvic nodes. Avoidance structures were created using isodose lines from previous prostate fossa radiation plans. Radiation was delivered using IMRT or VMAT techniques. Failure was defined as a confirmed rise of prostate-specific antigen (PSA) over 0.2 ng/mL.
Results: Four patients had presalvage PSA values <1 and 2 patients had PSAs >1. Dose to the clinical target volume was 54 to 60 Gy. The gross target volume dose was 60 to 73.6 Gy. One of the 2 patients with a high PSA received 6 months of concomitant ADT. Mean follow-up after RT for all patients was 24.9 months (range, 18.1 to 33.0 mo). All 5 patients with no ADT had significant PSA responses. PSA reduction was 80% (62% to 100%) of pre-RT PSA. At last follow-up, 2 patients with initial PSA<1 ng/mL remain free of biochemical progression at 33 and 20 months. Four patients have had PSA rise and meet criteria for failure. This included both patients with initial PSA values > 1. Duration of response before failure was 18.1 to 30.7 months. ADT for failure has been started in 1 patient. There was no grade ≥2 GI or GU toxicity.
Conclusions: Salvage lymph node irradiation for patients with early biochemical recurrence and radiologic evidence of pelvic nodal metastases is well tolerated and associated with a durable biochemical response and may be an alternative to or may delay the need for ADT in some patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/COC.0000000000000079 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Elective pelvic nodal irradiation for elderly patients with high-risk prostate cancer: A more patient-oriented approach.
Clin Transl Radiat Oncol
March 2025
Radiation Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy.
The role of elective pelvic nodal irradiation (EPNI) for high-risk prostate cancer (hrPC) management is still an open issue, especially for the elderly patients. It is unclear whether older patients can experience the same benefit from the treatment strategies used for younger men. Hence, in absence of solid data, it appears reasonable to pursuit a shared decision-making process so that older patients can express their informed preferences about the different treatment options.
View Article and Find Full Text PDFSimultaneous integrated boost intensity-modulated radiation therapy targeting clinically involved extramesorectal lymph nodes in locally advanced rectal cancer: A retrospective study.
Colorectal Dis
January 2025
Department of Radiation Oncology, Tata Memorial Centre, Mumbai, India.
Aim: Consensus is lacking regarding the management of extramesorectal lymph nodes (EMLN) in rectal cancer. Using simultaneous integrated boost intensity-modulated radiation therapy (SIB-IMRT), we targeted involved EMLN and reserved lateral pelvic lymph nodal dissection (LPLND) for nonresponders. The primary aim of this work was to determine the proportion of patients who avoided LPLND and to establish the pathological EMLN positivity rate.
View Article and Find Full Text PDFUtility of systemic staging in breast cancer patients with a positive sentinel lymph node biopsy.
Ir J Med Sci
January 2025
Department of Breast Surgery, St. Vincent's University Hospital, Dublin 4, D04 T6F4, Ireland.
Background: CT thorax, abdomen and pelvis (CT-TAP) remains the standard in the identification of metastatic disease in patients with newly diagnosed breast cancer. In patients with proven micro and macro axillary nodal metastasis, the optimal radiological technique remains controversial. A consensus on which patients with axillary nodal disease should receive radiological staging for distant disease and how this should be performed is not currently available.
View Article and Find Full Text PDFImpact of the Number of Positive Pelvic Lymph Nodes on Risk of Para-Aortic Recurrence in Patients with Clinically Early Cervical Cancer Treated by a Radical Hysterectomy and Pelvic Lymphadenectomy.
Cancers (Basel)
December 2024
Department of Gynecological Oncology, Centre for Gynecologic Oncology Amsterdam (C.G.O.A.), Amsterdam University Medical Center, 1081 HV Amsterdam, The Netherlands.
Background: Guidelines recommend the extension of the pelvic radiotherapy volume to the para-aortic region in locally advanced cervical cancer and ≥3 suspicious pelvic lymph nodes (PLN) on imaging. Whether this recommendation is also valid for clinically early stages is uncertain. The objective of this study was to investigate the para-aortic (PAO) lymph node recurrence rate in patients with early-stage cervical cancer, ≥3 metastatic PLN, and negative common iliac nodes after a radical hysterectomy followed by pelvic (chemo)radiotherapy without extension to the PAO region.
View Article and Find Full Text PDFPelvic Regional Control With 25 Gy in 5 Fractions in Stereotactic Radiation Therapy for High-Risk Prostate Cancer: Pooled Prospective Outcomes From the SHARP Consortium.
Int J Radiat Oncol Biol Phys
January 2025
Department of Radiation Oncology, University of California, Los Angeles, California.
Purpose: To evaluate the efficacy of 25 Gy in 5 fractions (25 Gy/5#) prophylactic pelvic nodal irradiation for regional control during stereotactic radiation therapy (SBRT) for high-risk prostate cancer.
Methods And Materials: The multinational SHARP consortium database of patients treated with curative-intent prostate SBRT for high-risk prostate cancer was queried for prophylactic radiation therapy 25 Gy/5# to the pelvic lymph nodes. Details of Phoenix-defined biochemical failure and location of recurrence (local, regional, or distant) were extracted.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!